“Dermatologist Tested” Means a Dermatologist Was There

There is a category of phrase on a cosmetic box that reads like a certification and is not one.

Dermatologist tested. Non-comedogenic. Hypoallergenic. Clinically proven. Suitable for all skin tones. For sensitive skin.

None of these has an FDA legal definition. There is no mandated testing standard behind any of them, no protocol a manufacturer must follow, and no threshold a product must clear before printing them.

Dermatologist tested means a dermatologist was involved in some testing. It does not say how many people, for how long, with what endpoint, or what the result was. A product can be dermatologist tested and have performed badly.

Non-comedogenic has an origin — a rabbit ear assay from the 1970s, which has been criticized for decades as a poor predictor of human comedogenicity — and no current requirement to have done anything at all.

For all skin tones is the one I want to sit on, because it is the claim most likely to be doing real work for a reader of this section. There is no shade-range testing requirement in US cosmetic law. No minimum number of shades, no requirement to test on any particular range of skin, no definition of “all.” The narrowest shade range on the shelf can print it beside the widest one, and the sentence carries identical legal weight, which is none.

A 2018 study in the Journal of Dermatological Treatment set out to audit the clinical evidentiary basis for exactly these over-the-counter marketing terms. It is linked below; the findings are behind a paywall I did not pay, so I am not going to characterize them. The fact that somebody thought the audit was necessary tells you what they expected to find.

MoCRA, which is real and does less than the headlines suggested

The Modernization of Cosmetics Regulation Act passed in 2022 and was widely described as the first meaningful overhaul of US cosmetic regulation since 1938. That framing is fair for what it does.

Facility registration and product listing became mandatory, with a December 2023 deadline. As of 6 January 2026 the FDA reported 14,299 unique active facility registrations and 992,907 unique active product listings, with renewal required every two years.

Adverse event reporting became mandatory, and the FDA launched a public-facing cosmetics adverse event dashboard on 12 September 2025 — genuinely useful, and worth knowing exists, because it means you can look up whether other people have reported reactions to a product.

What MoCRA does not do is require pre-market approval, ingredient safety review before sale, or substantiation of any of the marketing claims above.

And then the talc rule

MoCRA section 3505 directed the FDA to establish standardized testing methods for detecting asbestos in talc-containing cosmetics. Talc and asbestos occur in the same geological deposits; the contamination risk is a mineralogical fact, and it has been the subject of two decades of litigation.

The FDA issued a proposed rule on 27 December 2024.

It withdrew the proposed rule on 28 November 2025.

The stated reasons, per the Federal Register notice: 49 technical comments, concerns about unintended effects on other talc-containing consumer products, inconsistency with OSHA, MSHA and EPA definitions, questions about the agency’s statutory authority, and explicit reference to Make America Healthy Again policy priorities. The agency said it would issue a proposed rule to meet its statutory obligations, and gave no timeline.

So as of September 2026 there is no mandatory federal asbestos-testing standard for talc cosmetics. The statutory requirement exists. The rule implementing it does not.

The PFAS provision has gone a similar way — the FDA issued an assessment report on 29 December 2025 concluding that significant uncertainty remains regarding the safety of PFAS in cosmetics because of data gaps. No determination, no restriction.

Why this lands unevenly

Talc products marketed to Black and Latina consumers have been the subject of sustained litigation and advocacy — a Black women’s advocacy organization sued Johnson & Johnson alleging that talc-based baby powder was marketed specifically to Black and Latina women as awareness of contamination risk grew internally and sales declined elsewhere. That is an allegation in litigation, drawing on investigative reporting, not an adjudicated regulatory finding, and it should be read as the former.

I also went looking for an FTC enforcement action naming a skin-lightening or hair-relaxer company for deceptive claims aimed at these consumers, and did not turn one up. I cannot tell you that none exists, only that I did not reach one — which is worth recording either way, given how much litigation and congressional attention the talc question has drawn.

The general pattern: the categories with the thinnest regulation are the categories serving the consumers with the least regulatory attention. Relaxers with a formaldehyde rule promised since 2023 and never proposed. Lightening creams that moved to unregulated channels after 2020. Talc without a testing method. And “for all skin tones” printed on a box whose shade range stops a long way short of all.

What a phrase on a box is worth

Almost nothing, individually. Something, in aggregate, as a signal about who the brand thinks it is talking to.

The claims with actual content are the ones that name a number or a test — an SPF value, which is a measured protocol; a percentage concentration of an active; a named clinical trial you can look up. Everything else is copy.

And the one new thing genuinely worth using is the adverse event dashboard. If a product did something strange to your face, you can now look up whether it did it to anybody else, and you can add yours. That is more regulation than existed three years ago, and it is the part nobody reported.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.